Coagulation factor 9

Description

Extracted from Iranian plasma containing 500 international units concentrated Factor IX per vial and produce under commercial name of “Heamonine” by biotest Company from Germany and 600 international units per vial under commercial name of “Berry nine” by CSL Behring company from Switzerland.

Medical Group

A systematic drug for bleeding prevention

Medicine types

500 injective units

Vial compounds

Effective material: coagulation factor 9 extracted from human plasma (IU/vial 500)

Medical uses

Prevention and treatment of bleeding in type B hemophilia (factor IX Congenital deficiency)

Prohibited usage

—

Indications and dosage

Administrate through slow intravenous injection, dosage determined individually based on  patients need, severity of factor IX lack, the desirable concentrations of factor IX, body weights and bleeding severity.

Warnings and precautions

—

Side effects
  • there are reports on nephrotic syndrome in patients with type B Hemophilia with a history of allergic reactions.
  • Potential production of factor IX inhibitors
  • Potential thromboembolism (blood clots) in type B hemophilic patients
  • Unspecified Allergic or hypersensitive reactions are rare
  • Heparin in low amounts can causes allergic reaction and blood cells reduction
Storage and shelf-life
  • stored in 25°F
  • protect it from freezing
  • protect it from light and keep it in box
  • After preparing the solution should be used immediately

Related Products

hari

Anti-rabies human immunoglobulin

1-300-dar-300

Coagulation factor 8

2-300-dar-300

FH human albumin solution

3-300-dar-300

Intravenous human immunoglobulin

factor-9

Coagulation factor 9